Previous / Next

[20110219. Reprocessing endoscopes (2) - Endoscopy-related infections]

³»½Ã°æ °Ë»ç¿Í °ü·ÃµÈ °¨¿°ÁõÀº 4 °¡Áö·Î ³ª´­ ¼ö ÀÖ½À´Ï´Ù.

1) Patient to patient transfer: Salmonella¿Í Pseudomonas °¨¿°ÀÌ ¹®Á¦ÀÔ´Ï´Ù. Strongyloides, Mycobacterium tuberculosis, HBV, HCV, Helicobacter pylori °¨¿°µµ °¡´ÉÇÕ´Ï´Ù. ´ÙÇེ·´°Ôµµ ¾ÆÁ÷±îÁö ³»½Ã°æÀ» ÅëÇÑ HIV °¨¿°Àº ¾ø¾ú½À´Ï´Ù. ¸¸¾à ³»½Ã°æÀ» ÅëÇÑ HIV °¨¿°ÀÌ ´Ü ÇÑ °ÇÀÌ¶óµµ ¹ß»ýµÈ´Ù¸é ÇâÈÄ ³»½Ã°æ °Ë»ç¸¦ ¹Þ°íÀÚ Çϴ ȯÀÚÀÇ ¼ö´Â ±Þ°¨ÇÒ °ÍÀÔ´Ï´Ù. ¼­¾ç¿¡¼­´Â universal precautionÀ» °­Á¶ÇÏ°í ÀÖ½À´Ï´Ù. Áï ¸ðµç »ç¶÷ÀÌ AIDS, CÇü °£¿°, °áÇ٠ȯÀÚ¶ó°í °¡Á¤ÇÏ°í ¿¹¹æ´ëÃ¥À» °­±¸Ç϶ó´Â °ÍÀÔ´Ï´Ù. ±×·¯³ª ¿ì¸® Çö½Ç¿¡¼­´Â universal precautionµµ Áß¿äÇÏÁö¸¸ high risk patient¿¡ ´ëÇÑ Æ¯º° °ü¸®µµ ÇÊ¿äÇÏ´Ù°í »ý°¢ÇÕ´Ï´Ù.

2) Bacteremia: EGD ÈÄ 4.2%, ERCP ÈÄ 2.2%, colonoscopy ÈÄ 2.2%, sigmoidoscopy ÈÄ 4.9%, esophageal dilatationÈÄ 45%, variceal sclerotherapy ÈÄ 31%¿¡¼­ ±ÕÇ÷ÁõÀÌ ¹ß»ýÇÕ´Ï´Ù. ½ÉÁúȯÀÚ¿¡¼­ ³»½Ã°æ °Ë»ç¸¦ ÀüÈÄÇÑ antibiotic prophylaxis¿¡ ´ëÇÑ ¿¬±¸´Â Àû½À´Ï´Ù. º¸Åë Á¶Á÷°Ë»ç¸¦ Æ÷ÇÔÇÑ ³»½Ã°æ°Ë»ç¿¡¼­´Â ¿¹¹æÀû Ç×»ýÁ¦°¡ ÇÊ¿ä¾øÀ¸¸ç sclerotherapy³ª esophageal dilatation µî¿¡´Â ½ÉÀåÁúȯÀÌ ÀÖ´Â »ç¶÷¿¡¼­¸¸ ¿¹¹æÀû Ç×»ýÁ¦°¡ ±ÇÀ¯µÇ°í ÀÖ½À´Ï´Ù.

3) Aspiration pneumonia: ÈíÀμº Æó·ÅÀº ³»½Ã°æ ¼Òµ¶ÀÇ ¹®Á¦¶ó±â º¸´Ù´Â ½Ã¼ú ÀÚü¿¡ µû¸¥ À§Ç輺ÀÔ´Ï´Ù. °Ç°­ÇÑ »ç¶÷¿¡¼­ ÈíÀμº Æó·ÅÀÇ À§ÇèÀº ¸Å¿ì ³·Áö¸¸, ÁßÃ߽Űæ°è ÁúȯÀ̳ª ÅðÇ༺ ÁúȯÀÌ ÀÖ´Â °í·ÉÀÇ È¯ÀÚ¿¡¼­´Â Á¾Á¾ ¹ß»ýÇÕ´Ï´Ù. EMR/ESD¿Í °°ÀÌ Àå½Ã°£ÀÇ ½Ã¼úÀÌ ÇÊ¿äÇÑ °æ¿ì³ª PEG ½Ã¼ú½Ã ´õ¿í ÁÖÀÇÇØ¾ß ÇÕ´Ï´Ù. ÀÇ·áÁøÀÌ ¾Æ¹«¸® ÁÖÀÇÇÑ´Ù°í ÇÏ´õ¶ó°í ÈíÀμº Æó·ÅÀ» ¿Ïº®È÷ ¹æÁöÇϱâ´Â ¾î·Æ½À´Ï´Ù. ½Ã¼ú¿¡ µû¸¥ À§Ç輺À» °í·ÁÇÏ¿© ½Ã¼úÀ» ÇÒ °ÍÀÎÁö ¸» °ÍÀÎÁö¸¦ Àß °áÁ¤ÇÏ´Â °Í°ú »çÀü¿¡ Àß ¼³¸íÇÏ°í informed consent¸¦ ¹ÞÀ» °ÍÀ» ÃßõÇÕ´Ï´Ù.

4. Risks to staff: ³»½Ã°æ Àǻ糪 º¸Á¶ÀÚµµ ȯÀÚÀÇ Ç÷¾×, Ÿ¾× µî¿¡ ÀÇÇÏ¿© °¨¿°µÉ À§ÇèÀÌ ÀÖ½À´Ï´Ù. ±×·¯³ª ³»½Ã°æÀ» Çϸ鼭 Ç×»ó ¾Æ·¡ ±×¸²°ú °°Àº º¹ÀåÀ» ÇÒ ¼ö´Â ¾ø´Â ÀÏÀÔ´Ï´Ù.

[Home]